Discover a study where results suggest trends towards overall survival and progression-free survival improvements with ...

Adding pembrolizumab to CCRT improved survival outcomes in patients with high-risk, locally advanced cervical cancer.

Adding cabozantinib to first-line treatment with nivolumab and ipilimumab improved PFS — but not OS — in patients with RCC.

Progression-free survival (PFS), time-to-progression (TTP) and overall survival (OS) are commonly used endpoints in randomised controlled trials (RCTs) and observational studies of treatments for ...

Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.

SAN FRANCISCO -- Progression-free survival (PFS) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) more than doubled with the addition of the somatostatin analog (SSA) lanreotide ...

Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...

Progression-free survival (PFS): time a patient lives without disease progression. Overall survival (OS): time from diagnosis or treatment to death from any cause. After a median follow-up of 14 ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

Radiographic (r) PFS, freedom from castration, and overall survival (OS) all improved with MDT. Ongoing clinical studies will provide additional data to inform decisions about pursuing MDT ...